Feb 28, 2025 12:31 JST

Source: Eisai

Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone

TOKYO, Feb 28, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast growth factor (FGF) receptor selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, Japan brand name: TASFYGO®, “tasurgratinib”) in the Greater China region (mainland China, Hong Kong, Macau, and Taiwan, “licensed regions”) to a subsidiary of SciClone Pharmaceuticals (Holdings) Limited (Headquarters: Shanghai, China, “SciClone”). Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched.

Under the terms of this agreement, Eisai will receive a contractual upfront payment. Additionally, Eisai will receive milestone payments based on the progress of development and regulatory approval, as well as sales milestone payments and certain royalties based on sales revenue after the product launch.

Tasurgratinib is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against FGFR1, FGFR2 and FGFR3. Tasurgratinib was approved in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy. The medicine was launched in Japan in November 2024. A Phase I clinical trial (ClinicalTrials.gov, NCT04572295(New Window)) is underway in Japan for patients with estrogen receptor-positive and HER2-negative breast cancer.

SciClone is a global biopharmaceutical company with an integrated platform for the development and commercialization of innovative therapies for cancer and severe infection, and a strong presence in the Greater China region. Through the conclusion of this agreement, Eisai expects to maximize the value of tasurgratinib in licensed regions, ensuring the earliest possible contribution to patients in need of the medicine.

About SciClone Pharmaceuticals

Staying true to its original aspiration of “SciClone gives life hope”, SciClone Pharmaceuticals is dedicated to improving patients’ health by providing top-tier healthcare products and services with global standards of care. SciClone Pharmaceuticals has established a product portfolio with differentiated advantages, including a number of first-in-class and best-in-class potential products / pipelines.

For more information regarding SciClone Pharmaceuticals, please visit: www.sciclone.com and https://www.eisai.com/news/2025/pdf/enews202512pdf.pdf.

Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
March 25 2025 16:28 JST
 
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
March 25 2025 11:21 JST
 
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
March 10 2025 19:24 JST
 
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
March 05 2025 08:09 JST
 
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
March 04 2025 16:22 JST
 
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
March 03 2025 14:41 JST
 
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
March 03 2025 12:53 JST
 
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
February 20 2025 12:29 JST
 
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
February 14 2025 11:09 JST
 
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
February 03 2025 16:23 JST
 
More Press release >>

Latest Press Release


More Latest Release >>